Literature DB >> 27050226

ALS-008176 for Respiratory Syncytial Virus Infection.

John P DeVincenzo, Matthew W McClure, John Fry.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27050226     DOI： 10.1056/NEJMc1516110

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  Discharge Criteria for Bronchiolitis: An Unmet Need.

Authors:  Cristina Garcia-Mauriño; Melissa Moore-Clingenpeel; Rebecca Wallihan; Katalin Koranyi; Bavani Rajah; Tiffany Shirk; Maria Vegh; Octavio Ramilo; Asuncion Mejias
Journal:  Pediatr Infect Dis J       Date:  2018-06       Impact factor: 2.129

Review 2.  Ongoing developments in RSV prophylaxis: a clinician's analysis.

Authors:  Fariba Rezaee; Debra T Linfield; Terri J Harford; Giovanni Piedimonte
Journal:  Curr Opin Virol       Date:  2017-05-10       Impact factor: 7.090

Review 3.  Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses.

Authors:  Jennifer A Pickens; Ralph A Tripp
Journal:  Viruses       Date:  2018-01-21       Impact factor: 5.048

Review 4.  Promising approaches for the treatment and prevention of viral respiratory illnesses.

Authors:  Nikolaos G Papadopoulos; Spyridon Megremis; Nikolaos A Kitsioulis; Olympia Vangelatou; Peter West; Paraskevi Xepapadaki
Journal:  J Allergy Clin Immunol       Date:  2017-07-21       Impact factor: 10.793

5.  A quantitative exploration of symptoms in COVID-19 patients: an observational cohort study.

Authors:  Gaojing Qu; Junwen Chen; Guoxin Huang; Meiling Zhang; Hui Yu; Haoming Zhu; Lei Chen; Dengru Wang; Bin Pei
Journal:  Int J Med Sci       Date:  2021-01-01       Impact factor: 3.738

Review 6.  Respiratory syntycial virus: Current treatment strategies and vaccine approaches.

Authors:  Elena Margret Thornhill; Jessica Salpor; David Verhoeven
Journal:  Antivir Chem Chemother       Date:  2020 Jan-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.